RobertBrianBerrymanMD

PubMed

• 31 citations
  Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
  Paul J. Shaughnessy, Joseph P. Uberti, Steve Devine, Richard T. Maziarz, Julie M. Vose
  Bone Marrow Transplantation. 2013-06-01
• 27 citations
  Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracy...
  Edward Agura, Barry Cooper, Houston Holmes, Estil Vance, Robert Brian Berryman
  The Oncologist. 2011-02-01

Journal Articles

• Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracy...  
  Edward Agura, Barry Cooper, Houston Holmes, Estil Vance, Robert Brian Berryman, Christopher Maisel, Sandy Li, Giovanna Saracino, Mirjana Tadic-Ovcina, and Joseph Fay, The Oncologist, 1/1/2011
• A Randomized, Placebo-controlled Trial of Oral Beclomethasone Dipropionate as a Prednisone-sparing Therapy for Gastrointestinal Graft-versus-host Disease  
  Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, et.al., Blood, 1/1/2007
• Evaluation of Thymic Output by Measurement of T Cell Receptor Gene Rearrangement Excisional Circles (TREC) In Patients Who Have Received Fludarabine  
  Aquino VM, Douek DC, Berryman RB, Johnson MJ, Jain VK, Collins RH, Leukemia & Lymphoma, 1/1/2003

Abstracts/Posters

• Brentuximab Vedotin Does Not Prolong QT/QTc Interval in Patients with CD30-positive Lymphomas
  Tae H Han, Robert W Chen, Ranjana Advant, Robert B Berryman, Scott E Smith, Andres Forero-Torres, Joseph David Rosenblatt, Mitchell Reed Smith, Jasmine M Zain, Naomi N..., ASCO 2012 Annual Meeting, Chicago, IL, 1/1/2012
• Prolonged Treatment with Brentuximab Vedotin (SGN-35) In Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large Cell Lymphoma (SALCL).
  A Forero-Torres, R Berryman, R Advani, N Bartlett, R Chen, M Fanale, AK Gopal, O O'Connor, R Olshefski, S Smith, LE Grove, J Matous, ASH 2011 Annual Meeting, San Diego, CA, 1/10/2011
• Brentuximab Vedotin (SGN-35) Treatment in Relapsed CD30-positive Hodgkin's Lymphoma Patients following Allogeneic Stem Cell Transplant: A Multicenter Case Series
  A Gopal, R Ramchandra, R Berryman, R Advani, R Chen, M Smith, M Cooper, A Engert, J Matous, J Zain, L Grove, N Hunder, O O'Conner, Seattle Genetics - EBMT 2011 Annual Congress, Paris, 1/3/2011
• Pharmacy, Baylor University Medical Center, Dallas, Texas. Medactionplan.Com as a Tool for Patient Education and Medication Management in the Blood and Marrow Transpl...
  Wenyu C PharmD, Pineiro M RPh, Ginsburg A PharmD, Reyes A RPh, Ueng C PharmD, Matta C CPh, Taschek M RPh, Agura E MD, Berryman R MD, Pineiro L MD, Vance E MD, Fay J MD, Tandem Meeting, 1/1/2009
• Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatm...
  Agura, E, Berryman, R, Fay, J, Pineiro, L, Tadic-Ovcina M, Vance E, Woelfel, R, ASH, 1/1/2008
• Phase II Study Of Clofarabine And Cytosine Arabinoside In Adult Patients With Relapsed AML And In Elderly Patients With Untreated AML Who Are At High Risk Of Anthracyc...
  Agura E, Berryman R, Cooper B, Fay J, Holmes H, Maisel C, Molina A, Pineiro L, Vance III, E, Journal of Clinical Oncology, 1/1/2007
• Prevention of Graft-Versus-Host Disease (GVHD) with Tacrolimus after Allogeneic Grafting for Hematological Malignancies following Sub-Myeloablative Conditioning
  Fay J, Saracino G, Agura e, Berryman B, Pineiro L, Vance E, ASH, 1/1/2006
• Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML who Are at High Risk of Anthracyc...
  Pineiro L, Berryman RB, Brougher L, Cooper B, De Leon A, Fay J, Holmes H, Maisel C, Molina A, Saracino G, Tadic-Ovcina M, Vance E, ASH, 1/1/2006
• Comparison of CD34+ Collections in Patients with Multiple Myeloma Using Etoposide/cyclophosphamide + G-CSF, Cyclophosphamide + C-CSF, and G-CSF Alone Mobilization Regi...
  Scott, LM, Brougher LI, Anderson-Rietz L, Ensley L, Saracino G, Agura ED, Berryman RB, Fay JW, Pineiro L, Vance EA, ABMTR/IBMTR, Honolulu HI, 1/1/2006
• Modification of the Bu/Cy Myeloablative Regimen Using Daily Parenteral Busulfan: Reduced Toxicity without the Need for Pharmacokinetic Monitoring
  Mamlouk K, Saracino G, Berryman RB, Fay JW, Pineiro LA, Vance EA, White M, Sandler I, Agura ED, Bone Marrow Transplantation, 1/1/2005
• Results of Once Daily Parenteral Busulfan (Busulfex(R)) With Cyclophosphamide versus Intermittent Dosing of Busulfan with Cyclophosphamide as a Preparative Regimen for...
  Mamlouk K, White MJ, Berryman RB, Fay JW, Piñeiro LA, Vance EA, Agura ED, Tandem BMT Meeting, 1/1/2004
• Multidisciplinary Approach to Development of GVHD Outpatient Clinic
  Yount, P, Vance EA, Agura, ED, Berryman RB, Fay JW, Piñeiro L, Bengtson E, Bair JD, Tandem BMT Meeting, 1/1/2004
• Diseases Treated, Types Of Transplants, Regimen And Outcomes In An Outpatient Blood And Marrow Transplant Program
  Wilson, MC, King J, Scott, LM, Pierce, TN, Shamlou R, Saracino G White M, Agura E, Berryman RB, Fay JW, Piñeiro, L, Vance EA, ABMTR/IBMTR Meeting, 1/1/2003
• The effects of HLA Mismatches on the Outcome of Unrelated Donor-Bone Marrow Transplants in the Treatment of Chronic Myelogenous Leukemia
  Agura E, Saracino G, Fay J, Piñeiro L, Vance E, Berryman RB, Smith D, ASH Meeting, 1/1/2003
• Clinical Validation of Pentaspan(R) And Dimethylsulfoxide (DMSO) As Cryopreservant for Peripheral Blood Stem Cell Transplantation
  Piñeiro L, Murphy J, Agura E, Vance E, Berryman RB, Fay J, 9th Annual Meeting ISCT, 1/1/2003
• Development and Utilization of a Unified Strategic Business Plan for Marketing Blood and Marrow Transplant Outpatient Clinic Services. the Goal Is to Increase Awarene...
  Mcbane JI, Agura ED, Berryman RB, Fay JW, Piñeiro L, Vance EA, Wilson MC, ABMTR/IBMTR Meeting, 1/1/2003
• Changing Patterns of Fungal Infections in a Blood and Marrow Transplant Program
  White M, Scott LM, Mann L, Shamlou R, Saracino G, Agura ED, Berryman RB, Fay JW, Piñeiro L, Vance EA, ABMTR/IBMTR Meeting, 1/1/2003
• Utilizing a Customized Epidemiological, Drug-susceptibility Database to Monitor Resistance Patterns and Trends to Make Appropriate Empiric Antibiotic Selections for Bl...
  White M, Mamlouk K, Saracino G, Shamlou R, Agura ED, Berryman RB, Piñeiro L, Fay JW, Mann L, Vance E, ABMTR/IBMTR Meeting, 1/1/2003
• CD34+ Counts after Etoposide and Cyclophosphamide plus G-CSF Mobilization versus G-CSF Alone in Multiple Myeloma Patients Undergoing Autologous Transplantation
  Pierce TN, Scott LM, White M, Agura E, Berryman RB, Fay JW, Vance E, Piñeiro L, ABMTR/IBMTR Meeting, 1/1/2003
• Use of Amplicor CMV Monitor (Roche) For CMV Surveillance after Blood and Marrow Transplantation
  Mann L, White MJ, Piñeiro L, Peterson C, Agura ED, Fay JW, Berryman RB, Meyer R, Vance EA, ABMTR/IBMTR Meeting, 1/1/2003
• Join now to see all